I've lost 5 stone on MJ & gained 8lbs trying to come off – I'm panicking about new cost but I'll rack up debt if need be
Click to share on Facebook (Opens in new window)
A WOMAN who's lost almost five stone on Mounjaro has admitted she's willing to get herself into debt to stay on it amid the upcoming price hike.
The fat jab community was left panicked when GLP-1 supplier Eli Lilly announced they will be increasing their prices by up to 170% from 1st September.
Sign up for Scottish Sun
newsletter
Sign up
6
Chloe-Lou was left in an "instant panic" after hearing the prices of Mounjaro are set to dramatically increase in September
Credit: TikTok/@bamboowoolston
6
She's been on the GLP-1 drug for the past 14 months, and has lost 4st 11lbs to date
Credit: TikTok/@bamboowoolston
6
She's now virtually unrecognisable from her former self
Credit: TikTok/@bamboowoolston
6
Being on Mounjaro has also led to Chloe-Lou "reversing" her PCOS and getting a new lease of life
Credit: TikTok/@bamboowoolston
So the price of a 12.5mg Mounjaro pen is likely to go from £139 to a whopping £236 - leaving users terrified they'll be forced to come off the "miracle" drug.
One person who went into an "instant panic" after hearing news of the upcoming price hike is 34-year-old Chloe-Lou, who has lost 4st 11lbs in 14 months on the jabs and has been documenting her journey on TikTok.
To date, she hasn't struggled to afford the pens, as she's spending what she previously shelled out on junk food to be able to buy the Mounjaro.
But come September, she and millions of other users will have to take a hard look at their financial situation to work out if they can afford to stay on the pens.
Read more Mounjaro stories
JABS UP Ultimate guide to beat Mounjaro price hike - from jab switch to getting FREE on NHS
"When I heard about the price hikes I felt totally deflated," nail tech and mum Chloe-Lou, from Woolston, Southampton, told Fabulous Online.
"I know things rise in cost all the time but hearing the price is set to rise by 170% put me in an instant panic."
The situation is made doubly scary for Chloe-Lou, as she's previously tried "all sorts" of diets to lose weight, but hasn't been successful until Mounjaro because of her PCOS (polycystic ovarian syndrome).
She's also panicking because she has tried coming off Mounjaro before - and ended up gaining 8lbs in two months when she did so.
Luckily, her husband has said he'll cover the extra cost so that she can stay on the shots.
But Chloe-Lou admitted she would even consider putting herself into debt by using credit cards or payment plans like Klarna to afford Mounjaro if she had to.
I've lost 3.5st on Mounjaro in 6 months but its ruined so much
"I wouldn't want to rely on credit to continue but if it was my only option I think I'd have to consider using my credit card or the likes of Klarna," she said.
Mounjaro users have taken to social media in their thousands to share their fears over the price hike.
And countless people have admitted they'll even consider "microdosing" - taking smaller doses of the pen to make it last longer.
However, as the jabs have an expiry of 30 days once they're used, doing so means users are putting themselves at risk by changing their dosage.
There are also people looking into getting the jabs on the black market - something Chloe-Lou also did before she started with a legit Mounjaro supplier.
"Before using Mounjaro I bought semaglutide off of the black market," she said, referring to the other GLP-1 drug, most often sold under the name Wegovy.
WHO IS ELIGIBLE FOR WEIGHT LOSS JABS ON THE NHS?
NHS eligibility for weight loss injections has expanded but still lags behind the number who could potentially benefit from taking them.
Wegovy, medical name semaglutide, is only available for weight loss through specialist weight management clinics.
Patients are typically expected to have tried other weight loss methods before getting a prescription.
They may be eligible if their body mass index (BMI) is higher than 30, or higher than 27 if they have a weight-related health condition such as high blood pressure.
Mounjaro, known as tirzepatide, is also available from GP practices but currently only to patients with a BMI of 40 or higher (or 37.5 if from a minority ethnic background) plus four weight-related health conditions.
The medicines are currently being rationed to the patients most in need.
NHS watchdog NICE estimates that more than three million Brits will ultimately be eligible.
The GLP-1 injections are prescribed separately by GPs for people with type 2 diabetes, and patients should discuss this with their doctor.
"It made me poorly, and it made my asthma symptoms 10 times worse."
But Chloe-Lou admitted even her friends are considering buying on the black market so they can afford the jabs.
And she fears struggling to afford the jabs will mean a huge impact on people's mental health.
"I'm so worried that after working wonders reversing my PCOS and giving me a new lease of life that people who have no choice but to end their treatment will become depressed," she sighed.
How to get free debt help
There are several groups which can help you with your problem debts for free. Citizens Advice - 0800 144 8848 (England) / 0800 702 2020 (Wales)
- 0800 144 8848 (England) / 0800 702 2020 (Wales) StepChange - 0800138 1111
- 0800138 1111 National Debtline - 0808 808 4000
- 0808 808 4000 Debt Advice Foundation - 0800 043 4050
You can also find information about Debt Management Plans (DMP) and Individual Voluntary Agreements (IVA) by visiting MoneyHelper.org.uk or Gov.UK.
Speak to one of these organisations - don't be tempted to use a claims management firm.
They say they can write off lots of your debt in return for a large upfront fee.
But there are other options where you don't need to pay.
"Especially after how I felt being off the drug for 8 weeks - gaining weight and having uncontrollable hunger.
"I can see it having a huge impact on people's mental health, especially if they start to regain weight."
6
Chloe-Lou came off the drug for two months, and ended up gaining 8lbs in that time
Credit: TikTok/@bamboowoolston
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
3 hours ago
- Times
What to do now Mounjaro's hiking its prices, by an obesity expert
In disappointing news for doctors and patients across the UK, the weight-loss jab Mounjaro is the latest casualty of global politics. Last week Eli Lilly, the US-based manufacturer of the weight-loss jab, said it would be doubling its prices for UK pharmacies. The price jump comes a month after President Trump demanded that pharmaceutical businesses lower prices for American patients and stop other countries 'freeloading' off US firms. From September the rate for a middle-sized 5mg dose will nearly double, from £92 to £180. The maximum dose, 15mg, will increase from £122 to £330. While this won't have an affect on the NHS, it will for the 1.5 million people in the UK who are buying the drug privately from online services and high street pharmacies. So what will be the consequences of these price hikes and what should Mounjaro users do? My advice is that if you can find a way to stay on Mounjaro, then you should try to, if it has improved your life. It's a popular drug among private providers because they can prescribe it for weight management to a wider range of people who meet licensed BMI and health condition criteria. Most patients won't be on the full 15mg dose so, while prescriptions will still cost significantly more, most people will find the maximum price won't apply to them. The most likely reaction from patients will be to lower their dose to pay a smaller price. The consequences of that are simple: if you move to a lower dose, you may regain some weight, because the amount of the chemical that's suppressing your appetite will be less. What's important to remember is that your weight will not go anywhere near what it was when you first started the injections, and there will still be a considerable degree of appetite control. Switching to a potentially more affordable alternative such as Wegovy, which is produced by Novo Nordisk and will not be increasing prices (£100-£200 a month from private online pharmacies), will probably have a similar consequence to cutting the dosage, because it is not as potent. Research has found Mounjaro at the 15mg dose reduced body weight in people with obesity by just over 20 per cent, whereas Wegovy at its top dose of 2.4mg cut it by nearly 14 per cent, a similar level of weight achieved by 5mg of Mounjaro. • The weight-loss drugs guide: how to avoid the side effects Switching between weight-loss drugs isn't an entirely seamless process either. Before taking Wegovy (which is also sold as Ozempic for diabetes treatment), you would need to stop Mounjaro for five weeks and begin your new drug on a low dose. Weight gain is highly likely, but it should be relatively modest, given the short period off the medicines. Those who don't live with obesity may ask why people need medical intervention to lose weight in the first place, but drugs like Mounjaro are proven to improve health in myriad ways. In most cases, they contribute to sustainable weight loss, which improves a patient's relationship with food, cuts calorie consumption and improves many risk factors, including blood pressure and blood sugar and liver fat levels. It also makes you less likely to get diseases like type 2 diabetes and decreases the risk of having a heart attack or stroke. For those already living with heart failure and sleep apnoea, symptoms improve substantially. For those with osteoarthritis, weight-loss drugs can help to decrease knee pain by a third and if you have liver or kidney disease, its progression is slowed. While many headlines focus on possible side-effects such as nausea, these usually only last for the first few weeks and are often caused by the transition for some of going from eating a lot of calories to a much more modest number. The vast majority of people on weight-loss drugs are doing fine and enjoying better appetite control and reduced snacking. Weight loss usually plateaus at around one year to 18 months and, judging by the trials, average weight loss will be somewhere between 10 per cent and 25 per cent. • Weight-loss drugs herald new era of cancer prevention To some extent, the increased prices could have a positive effect. For those who lower their dose or make the transition to another brand, it may lead to deeper consideration of what else they can do to mitigate the consequences, like walking more or finding other activities they may enjoy. The truth is that we don't yet know what effect the higher prices will have, or how those buying private weight-loss medication will react. For professionals like me, it feels like we're about to embark on a big public health experiment, comparable to when the government increased the price of cigarettes. This time, though, in terms of health, price increases are taking us in the wrong direction. It's disappointing because so many people are doing well on Mounjaro. The wider context is that our food environment is not changing quickly enough and, until it does, more and more people are going to be living with obesity. For now, we have these new drugs in place to help and we want them to be cheaper, not more expensive. We want more people to benefit from them because, if we are to go by the studies we have so far, the health benefits substantially outweigh the worst thing is that the new prices make access to the drug even more difficult for the poorest people in society, and they are who need it the most. Sadly, the increased cost is another ramification of current global politics but if your health and quality of life were much improved on the medicine and you can save a bit of money elsewhere and maintain your Mounjaro prescription, the extra costs I would urge you to do so. Naveed Sattar is professor of metabolic medicine at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow and an honorary consultant in metabolic medicine at the Glasgow Royal Infirmary. He has consulted for Eli Lilly and Novo Nordisk but has never held shares in any medical company
Daily Mirror
6 hours ago
- Daily Mirror
Mum rushed to hospital and unable to smile after popping pimple on face
Mum-of-two Alisha Monaco immediately became dizzy before suffering horrific pain in her face and waking up five hours later with a swollen face and unable to smile A woman who popped a spot in what has been labelled the little-known "triangle of death" on her face was rushed the hospital when she became dizzy and suffered "excruciating" pain. Alisha Monaco was completely unaware it was dangerous to pop a spot in the area between the corners of the mouth and the bridge of the nose. This is due to the connection to the cavernous sinus - a region in the brain - with picking or squeezing pimples potentially leading to serious infections. Alisha detailed the incident in a TikTok which has had more than 7.8 million views where she said it appeared to be an "average" spot, which she claims she is prone to getting several times a month. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. After she failed to pop it, Alisha decided to poke it with a sanitised pimple popper needle tool, with her ear popping at the same time before she became immediately dizzy. The 32-year-old, who lives in Michigan, said: "I knew I'd messed up. "The pain was all on the right bottom side of my nostril, down to my lip and even up the side of my face. I woke up four or five hours later in excruciating pain on my right side of my face. "The whole right side of my face was swollen, my smile was crooked and my ear felt clogged on the right side. It was brutal. I was in so much pain just trying to smile/talk." The mum-of-three rang her husband and asked him to come home to be with their children while she went to get seen to. Alisha continued: "The urgent care staff was extremely kind to me and make a point to not let me feel embarrassed about being at the urgent care for popping a pimple. "They were happy I came in because the swelling was so bad. I needed to get it treated immediately because the risk of infection in that location is dangerous." Alisha was prescribed four different medications to keep her symptoms at bay as well as stopping the risk of the infection spreading before being allowed to leave hospital. She has since been recovering at home and has taken to TikTok to share the dangers of popping a spot in the "triangle of death" She said: "I had a feeling after I popped the pimple that I needed to look it back up on TikTok to double check and sure enough my pimple was right in the triangle of death area. I [then] just wanted to warn others to learn from my experience. "I don't have a huge following on social media so I had no idea that it was going to go so viral, but from reading the comments of all the people who weren't aware that the triangle of death was a thing, I'm glad I did. Now everyone can see what happened to me and hopefully they will just put a pimple patch on and leave that area alone."
The Sun
7 hours ago
- The Sun
Mounjaro vs Wegovy: From side effects to max weight loss, how top fat jabs compare – as price hike looms
WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss jabs compare in their success, side effects and price? 4 People paying privately for Mounjaro in the UK face a rise in the cost of treatment after manufacturer Eli Lilly announced on Thursday it was increasing the list price by as much as 170 per cent. The change means the suggested price for a month's supply of the highest dose of the medicine will increase from £122 to £330 (for the provider). While retailers who sell Mounjaro may be able to negotiate discounts, it's likely the price will increase at least somewhat for the estimated 1.5 million people on weight loss drugs in the UK. GP Dr Ross Perry, medical director of Cosmedics skin clinics, is one of a number of medics who predict the price change will influence patient choice over what and which weight loss treatment to opt for. Mounjaro and Wegovy are similar in that they both belong to a group of medications called glucagon-like peptide 1 (GLP-1) receptor agonists. But there are a host of differences between the two. Dr Perry says: "Wegovy has a longer track record for weight loss and might be seen as a safer, more established option, but if Mounjaro becomes significantly more expensive, some patients may opt for Wegovy to save money, even if Mounjaro could deliver slightly greater weight loss. Our experts share the main differences between Mounjaro and Wegovy to be aware of that may influence whether you make the switch. What are the main differences? While both Wegovy and Mounjaro are injectable weight loss medications, they work slightly differently. Professor Franklin Joseph, head of Dr Frank's weight loss clinic, explains: "Wegovy contains semaglutide, which mimics a hormone called GLP-1 that slows digestion, reduces appetite, and helps regulate blood sugar. "Mounjaro contains tirzepatide, which mimics GLP-1 but also another hormone called GIP. "That dual action appears to be the mechanism that gives Mounjaro a slightly stronger effect on appetite control and weight loss.' Do you take different doses? Wegovy and Mounjaro are both weekly injections intended for long-term use, but have different dosing schedules. Wegovy starts at 0.25mg weekly and is gradually increased to a maintenance dose of 2.4 mg, while Mounjaro begins at 2.5 mg weekly and can be stepped up to a maximum of 15 mg. This does not necessarily mean Mounjaro users start and end on the highest dose. The dosages are not directly comparable because they are different ingredients. "Neither is designed as a short-term treatment," says Dr Perry. "They are ongoing therapies for managing weight and, in some cases, blood sugar. "As long as they remain effective and side effects are manageable, they can be taken for years under medical supervision. "Stopping the medication often makes it harder to maintain weight loss and blood sugar control." Which one can help you lose more weight? Studies so far suggest Mounjaro may be more effective than Wegovy for weight loss. In clinical trials called 'SURMOUNT', sponsored by Eli Lilly, people on Wegovy lost around 15 per cent of their body weight on average over about 68 weeks, while those on Mounjaro lost up to 21 per cent in a similar time frame. "This is likely because Mounjaro works on two hormones (GLP-1 and GIP) instead of just one," says Dr Perry. But Professor Joseph adds: "Both are very effective compared to lifestyle measures alone, and the response can be very individual, with dramatic and life-changing weight loss occurring with both medications." For Toby Nicol, CEO of CheqUp, which provides weight loss injections, Mounjaro is the more effective medication. He says: "Both drugs are excellent for weight loss, but one way of looking at this is to consider that Mounjaro is a Ferrari, Wegovy is a Porsche, but the alternative (diet and exercise) is a horse and cart.' How do side effects differ? 4 Wegovy and Mounjaro share most of the same side effects because they work in similar ways. These mainly affect digestion, says Dr Perry. Common issues include nausea, vomiting, diarrhoea, constipation, and stomach pain or bloating. "The main difference is Mounjaro's dual action can sometimes make these effects feel stronger, especially in the early stages or when doses are increased," Dr Perry explains. "Some people also notice greater appetite suppression or changes in taste with Mounjaro. "But serious side effects, such as gallbladder problems or pancreatitis, are rare but possible with both medications." Clinical trials have also shown that Wegovy has a higher rate of nausea. Dr Perry says: "Forty-four per cent of users experience it, but only about 12 per cent of Mounjaro users report nausea." Is one better suited to certain people than the other? 4 Wegovy and Mounjaro are both suitable for adults with obesity or those who are overweight with weight-related health problems, but there are some differences in how they're typically prescribed. Dr Perry explains: "Wegovy is widely approved specifically for weight management, so it's often the first choice for people without diabetes who want a proven option with a longer safety track record in weight loss. "It may also be preferred for patients who are sensitive to stronger appetite suppression or digestive side effects. "Mounjaro was first approved for type 2 diabetes, so it's often prescribed to people who have both obesity and diabetes or prediabetes, as it can offer powerful blood sugar control alongside weight loss. "It's newer for obesity treatment, but may be chosen for people who want the potential for greater weight loss or who haven't achieved enough results with a GLP-1–only drug like Wegovy." Prof Joseph adds: " In the end, the choice often comes down to cost, availability, side effect tolerance, and a discussion between doctor and patient.' As to whether Prof Joseph thinks patients will make the switch from Mounjaro to Wegovy, he says: "Cost will definitely play a role. "These treatments are very expensive, and if Mounjaro becomes significantly pricier, many patients may switch to Wegovy, especially if their weight loss has been steady and they're tolerating it well. "For those who can afford it, Mounjaro's extra effectiveness may justify the higher price, but most patients are very cost-sensitive, so we're likely to see more people choosing Wegovy.' The Mounjaro announcement doesn't affect the price the NHS pays, as the service has negotiated a heavily discounted rate for those getting the drug on prescription. Find out if you could be eligible below...
